Loading...
XKRX950130
Market cap211mUSD
Aug 14, Last price  
9,060.00KRW
Name

Access Bio Inc

Chart & Performance

D1W1MN
XKRX:950130 chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
9.59%
Shrs. gr., 5y
6.29%
Rev. gr., 5y
54.01%
Revenues
348.64b
-66.28%
36,997,543,00045,840,015,00032,305,084,00035,582,621,00032,485,928,00029,464,754,00040,239,207,00043,058,688,000121,797,380,000505,111,695,0001,033,863,094,000348,643,147,000
Net income
-3.17b
L
7,451,130,0007,838,027,0002,432,290,0001,265,161,000304,159,000-6,485,782,000-4,240,612,000-20,656,016,00048,272,499,000189,689,851,000346,670,216,000-3,172,838,000
CFO
-103.88b
L
1,845,660,0001,587,126,000-2,748,909,0002,865,213,0002,553,507,000-5,445,311,000-5,730,652,000-422,239,00036,722,089,000163,476,864,000369,197,603,000-103,882,450,000
Dividend
Dec 28, 2022871 KRW/sh

Profile

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.
URL
https://accessbio.net/
IPO date
May 30, 2013
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
348,643,147
-66.28%
1,033,863,094
104.68%
505,111,695
314.71%
Cost of revenue
365,100,730
538,820,074
158,820,613
Unusual Expense (Income)
NOPBT
(16,457,583)
495,043,020
346,291,082
NOPBT Margin
47.88%
68.56%
Operating Taxes
(580,477)
113,950,620
66,683,149
Tax Rate
23.02%
19.26%
NOPAT
(15,877,106)
381,092,400
279,607,933
Net income
(3,172,838)
-100.92%
346,670,216
82.76%
189,689,851
292.96%
Dividends
(29,341,410)
Dividend yield
Proceeds from repurchase of equity
(1,959,192)
(28,048,211)
15,011
BB yield
6.11%
0.00%
Debt
Debt current
13,426,642
12,979,119
58,073,666
Long-term debt
109,082,792
114,049,447
25,946,858
Deferred revenue
635,799
594,761
Other long-term liabilities
1,110,070
Net debt
(260,767,745)
(355,893,600)
(121,058,315)
Cash flow
Cash from operating activities
(103,882,450)
369,197,603
163,476,864
CAPEX
(18,672,723)
(18,908,106)
(34,108,672)
Cash from investing activities
(46,490,664)
(37,754,066)
(34,929,743)
Cash from financing activities
(53,989,107)
(67,413,860)
18,005,445
FCF
(31,997,246)
345,107,460
227,262,334
Balance
Cash
346,976,330
498,714,243
200,332,592
Long term investments
36,300,849
(15,792,077)
4,746,247
Excess cash
365,845,022
431,229,011
179,823,254
Stockholders' equity
573,312,418
600,452,592
239,575,331
Invested Capital
291,451,212
262,278,375
167,341,524
ROIC
177.41%
222.60%
ROCE
71.38%
99.75%
EV
Common stock shares outstanding
34,866
37,632
36,998
Price
12,200.00
-23.75%
16,000.00
-27.44%
Market cap
459,116,000
-22.44%
591,971,456
-22.58%
EV
111,208,302
474,369,919
EBITDA
(497,741)
505,869,516
352,355,514
EV/EBITDA
0.22
1.35
Interest
3,710,714
6,233,160
3,349,680
Interest/NOPBT
1.26%
0.97%